Cancer Family
Hematopoietic and Lymphatic System Neoplasm
CI-CAN-00000022Explore in graph →
Non-malignant4,305 active trials98 approved drugs1,010 evidence items
- NCIt
- C35813
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000022Explore in graph →
Clinical trials
18,823 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02623439 | A Study of Haploidentical Bone Marrow Transplant for Patients With Hematologic Malignancies | terminated | Phase 2 | 10 | University of California, San DiegoOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT00776373 | Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies(UPCC 25406) | terminated | Phase 1 / Phase 2 | 4 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Nov 5, 2025 |
| clinicaltrials |
| NCT03837509 | INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 15 | Incyte CorporationINDUSTRY | 3 | Nov 4, 2025 | clinicaltrials |
| NCT04874194 | Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1 | terminated | Phase 1 / Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 3, 2025 | clinicaltrials |
| NCT04511130 | Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant(ARTEMIS) | terminated | Phase 2 | 92 | Marker Therapeutics, Inc.INDUSTRY | 1 | Oct 30, 2025 | clinicaltrials |
| NCT00726232 | Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia | terminated | Phase 2 | 73 | Incyte CorporationINDUSTRY | 2 | Oct 29, 2025 | clinicaltrials |
| NCT04035434 | A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON) | terminated | Phase 1 / Phase 2 | 93 | CRISPR Therapeutics AGINDUSTRY | 6 | Oct 24, 2025 | clinicaltrials |
| NCT04582539 | To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma(LIMBER) | terminated | Phase 1 / Phase 2 | 22 | Incyte CorporationINDUSTRY | 3 | Oct 22, 2025 | clinicaltrials |
| NCT03590652 | Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone as Salvage Therapy in Relapsed/Refractory Multiple Myeloma | terminated | Phase 2 | 23 | University of California, San DiegoOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT04541017 | Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment | terminated | Phase 1 / Phase 2 | 8 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2025 | clinicaltrials |
| NCT04623216 | Sabatolimab as a Treatment for Patients With Acute Myeloid Leukemia and Presence of Measurable Residual Disease After Allogeneic Stem Cell Transplantation. | terminated | Phase 1 / Phase 2 | 24 | Novartis PharmaceuticalsINDUSTRY | 4 | Oct 16, 2025 | clinicaltrials |
| NCT04501614 | A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | terminated | Phase 1 / Phase 2 | 11 | TakedaINDUSTRY | 15 | Oct 2, 2025 | clinicaltrials |
| NCT05579769 | Pediatric Study of GVHD Ppx w/o Calcineurin Inhibitors After Day60 Post First Allo HSCT for Hematological Malignancies. | terminated | Phase 2 | 3 | St. Jude Children's Research HospitalOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT01258933 | Ofatumumab for Minimal Residual Disease (MRD) and Maintenance Therapy | terminated | Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT03948529 | RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation(REGALIA) | terminated | Phase 2 | 9 | University Hospital, LilleOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT05148234 | BMS-986253 in Myelodysplastic Syndromes | terminated | Phase 1 / Phase 2 | 2 | National Cancer Institute (NCI)NIH | 1 | Sep 30, 2025 | clinicaltrials |
| NCT05358808 | ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)(ACHIEVE) | terminated | Phase 2 | 16 | TC BiopharmINDUSTRY | 1 | Sep 30, 2025 | clinicaltrials |
| NCT06018129 | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | terminated | Phase 1 / Phase 2 | 9 | GenmabINDUSTRY | 2 | Sep 25, 2025 | clinicaltrials |
| NCT03769181 | A Study of Isatuximab-based Therapy in Participants With Lymphoma | terminated | Phase 1 / Phase 2 | 58 | SanofiINDUSTRY | 7 | Sep 23, 2025 | clinicaltrials |
| NCT03860844 | Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia(ISAKIDS) | terminated | Phase 2 | 67 | SanofiINDUSTRY | 16 | Sep 9, 2025 | clinicaltrials |
| NCT02438761 | PF-05212384 (PKI-587) for t-AML/MDS or de Novo Relapsed or Refractory Acute Myeloid Leukemia (AML) (LAM-PIK)(5) | terminated | Phase 2 | 10 | Institut CurieOTHER | 1 | Sep 8, 2025 | clinicaltrials |
| NCT03564678 | Levocarnitine and Vitamin B Complex in Treating PEG-Asparaginase or Inotuzumab Ozogamicin-Induced Hyperbilirubinemia in Patients With Acute Lymphoblastic Leukemia | terminated | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 5, 2025 | clinicaltrials |
| NCT05222269 | [68Ga]Ga-PentixaFor PET Imaging in CNS Lymphoma Patients | terminated | Phase 2 | 1 | Pentixapharm AGINDUSTRY | 2 | Sep 5, 2025 | clinicaltrials |
| NCT05626322 | Effects of Maplirpacept (PF-07901801),Tafasitamab, and Lenalidomide in People With Relapsed or Refractory Diffuse Large B-cell Lymphoma | terminated | Phase 1 / Phase 2 | 6 | PfizerINDUSTRY | 3 | Sep 5, 2025 | clinicaltrials |
| NCT03646123 | Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma | terminated | Phase 2 | 255 | Seagen Inc.INDUSTRY | 6 | Aug 28, 2025 | clinicaltrials |
| NCT03376477 | Allogeneic Myeloma GM-CSF Vaccine With Lenalidomide in Multiple Myeloma Patients in Complete or Near Complete Remission | terminated | Phase 2 | 24 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 27, 2025 | clinicaltrials |
| NCT03769532 | MRD-guided Treatment in NPM1mut AML Patients(PEMAZA) | terminated | Phase 2 | 26 | Technische Universität DresdenOTHER | 1 | Aug 24, 2025 | clinicaltrials |
| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML | terminated | Phase 1 / Phase 2 | 24 | Sutro Biopharma, Inc.INDUSTRY | 9 | Aug 24, 2025 | clinicaltrials |
| NCT00015847 | Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia | terminated | Phase 2 | 25 | OHSU Knight Cancer InstituteOTHER | 1 | Aug 22, 2025 | clinicaltrials |
| NCT06508489 | A Study to Investigate Natural Killer Cell Engager (SAR443579) With Different Agents in Participants With Hematological Malignancies | terminated | Phase 1 / Phase 2 | 7 | SanofiINDUSTRY | 2 | Aug 22, 2025 | clinicaltrials |
| NCT05883449 | Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL(LuminICE-203) | terminated | Phase 2 | 25 | Affimed GmbHINDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT05032183 | Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma | terminated | Phase 1 / Phase 2 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT04433182 | Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma | terminated | Phase 2 | 37 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 8, 2025 | clinicaltrials |
| NCT03862131 | PROactive Evaluation of Function to Avoid CardioToxicity(PROACT) | terminated | Phase 2 | 49 | Washington University School of MedicineOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT04849910 | Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS | terminated | Phase 1 / Phase 2 | 67 | Vor BiopharmaINDUSTRY | 2 | Jul 29, 2025 | clinicaltrials |
| NCT05984199 | Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant | terminated | Phase 1 / Phase 2 | 38 | Vor BiopharmaINDUSTRY | 1 | Jul 29, 2025 | clinicaltrials |
| NCT05011058 | An Open-Label Phase 2 Trial of Nanatinostat Plus Valganciclovir in Patients With EBV+ Relapsed/Refractory Lymphomas(NAVAL-1) | terminated | Phase 2 | 102 | Viracta Therapeutics, Inc.INDUSTRY | 14 | Jul 28, 2025 | clinicaltrials |
| NCT03401853 | Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma | terminated | Phase 2 | 18 | University of WashingtonOTHER | 1 | Jul 22, 2025 | clinicaltrials |
| NCT05879458 | Ritlecitinib in CTCL | terminated | Phase 2 | 7 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jul 18, 2025 | clinicaltrials |
| NCT03287817 | Cluster of Differentiation Antigen 19/22(CD19/22) CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma(ALEXANDER) | terminated | Phase 1 / Phase 2 | 52 | Autolus LimitedINDUSTRY | 2 | Jul 14, 2025 | clinicaltrials |
| NCT02849886 | T Lymphocytes (LT) Expressing iCASP9 and ΔCD19 in Allogeneic Haematopoietic Transplantation.(Side_by_Cide) | terminated | Phase 1 / Phase 2 | 2 | Centre Hospitalier Universitaire de BesanconOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT03333486 | Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer | terminated | Phase 2 | 31 | Roswell Park Cancer InstituteOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT04103645 | Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients | terminated | Phase 2 | 2 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT03724084 | Pinometostat With Standard Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and MLL Gene Rearrangement | terminated | Phase 1 / Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Jun 18, 2025 | clinicaltrials |
| NCT03013491 | PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas | terminated | Phase 1 / Phase 2 | 196 | CytomX TherapeuticsINDUSTRY | 6 | Jun 17, 2025 | clinicaltrials |
| NCT05265975 | A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL(SWATCH) | terminated | Phase 1 / Phase 2 | 54 | Antengene CorporationINDUSTRY | 1 | Jun 9, 2025 | clinicaltrials |
| NCT01251965 | Phase l/II Study of Ruxolitinib for Acute Leukemia | terminated | Phase 1 / Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT02420717 | Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia | terminated | Phase 2 | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2025 | clinicaltrials |
| NCT05405309 | RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia(CORONADO CLL) | terminated | Phase 1 / Phase 2 | 5 | University of UtahOTHER | 1 | Jun 3, 2025 | clinicaltrials |
| NCT01350258 | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps | terminated | Phase 1 / Phase 2 | 8 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 31, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Nov 10, 2025source: clinicaltrials